SG10201914060WA - Anti-egfr antibody drug conjugates - Google Patents
Anti-egfr antibody drug conjugatesInfo
- Publication number
- SG10201914060WA SG10201914060WA SG10201914060WA SG10201914060WA SG10201914060WA SG 10201914060W A SG10201914060W A SG 10201914060WA SG 10201914060W A SG10201914060W A SG 10201914060WA SG 10201914060W A SG10201914060W A SG 10201914060WA SG 10201914060W A SG10201914060W A SG 10201914060WA
- Authority
- SG
- Singapore
- Prior art keywords
- drug conjugates
- antibody drug
- egfr antibody
- egfr
- conjugates
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title 1
- 229940049595 antibody-drug conjugate Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662347416P | 2016-06-08 | 2016-06-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201914060WA true SG10201914060WA (en) | 2020-03-30 |
Family
ID=59078219
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201810970WA SG11201810970WA (en) | 2016-06-08 | 2017-06-07 | Anti-egfr antibody drug conjugates |
SG10201914060WA SG10201914060WA (en) | 2016-06-08 | 2017-06-07 | Anti-egfr antibody drug conjugates |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201810970WA SG11201810970WA (en) | 2016-06-08 | 2017-06-07 | Anti-egfr antibody drug conjugates |
Country Status (21)
Country | Link |
---|---|
US (2) | US20190343961A1 (en) |
EP (2) | EP3468996B1 (en) |
JP (3) | JP2019521106A (en) |
KR (2) | KR20190015526A (en) |
CN (4) | CN116059202A (en) |
AU (1) | AU2017277517A1 (en) |
BR (1) | BR112018075636A2 (en) |
CA (1) | CA3027178A1 (en) |
CL (2) | CL2018003527A1 (en) |
CO (1) | CO2018013497A2 (en) |
CR (1) | CR20180614A (en) |
DO (2) | DOP2018000272A (en) |
EC (1) | ECSP19000157A (en) |
IL (3) | IL308054A (en) |
MX (2) | MX2018015286A (en) |
PE (1) | PE20190512A1 (en) |
PH (1) | PH12018502602A1 (en) |
RU (1) | RU2018147224A (en) |
SG (2) | SG11201810970WA (en) |
TW (2) | TW201806626A (en) |
WO (1) | WO2017214282A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109562190A (en) * | 2016-06-08 | 2019-04-02 | 艾伯维公司 | Anti-egfr antibodies drug conjugates |
SG10201914119TA (en) | 2016-06-08 | 2020-02-27 | Abbvie Inc | Anti-b7-h3 antibodies and antibody drug conjugates |
WO2018218004A1 (en) * | 2017-05-24 | 2018-11-29 | The Board Of Regents Of The University Of Texas System | Linkers for antibody drug conjugates |
KR102440763B1 (en) * | 2019-05-20 | 2022-09-05 | 맙플렉스 인터내셔널 컴퍼니 리미티드 | One-pot method for preparing intermediates of antibody-drug conjugates |
CA3136088A1 (en) | 2019-05-20 | 2020-11-26 | Matthew T. Burger | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
KR20210097627A (en) | 2020-01-30 | 2021-08-09 | 성균관대학교산학협력단 | Antibody-drug conjugate comprising immune checkpoint inhibitor and exosome secretion inhibitor and Pharmaceutical composition comprising the same |
US20230218778A1 (en) | 2020-05-19 | 2023-07-13 | Les Laboratoires Servier | Para-amino-benzyl linkers, process for their preparation and their use in conjugates |
WO2022115477A1 (en) | 2020-11-24 | 2022-06-02 | Novartis Ag | Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
UY39610A (en) | 2021-01-20 | 2022-08-31 | Abbvie Inc | ANTI-EGFR ANTIBODY-DRUG CONJUGATES |
KR20240024061A (en) * | 2021-06-22 | 2024-02-23 | 리제너론 파마슈티칼스 인코포레이티드 | Anti-EGFRvIII antibody drug conjugates and uses thereof |
WO2023208106A1 (en) * | 2022-04-29 | 2023-11-02 | 石药集团中奇制药技术(石家庄)有限公司 | Compound having liver-targeting delivery effect and oligonucleotide conjugate thereof |
WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
WO2023223097A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody drug conjugates |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1726514A (en) | 1926-11-01 | 1929-08-27 | Firm Ferd Liebschner & Sohn | Picker for looms |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
AU631802B2 (en) | 1988-06-14 | 1992-12-10 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5124471A (en) | 1990-03-26 | 1992-06-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Bifunctional dtpa-type ligand |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
ES2420835T3 (en) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedure to control the activity of immunofunctional molecules |
US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
WO2002000879A2 (en) | 2000-06-28 | 2002-01-03 | Glycofi, Inc. | Methods for producing modified glycoproteins |
EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
US20040192898A1 (en) | 2001-08-17 | 2004-09-30 | Jia Audrey Yunhua | Anti-abeta antibodies |
MXPA04003798A (en) | 2001-10-25 | 2004-07-30 | Genentech Inc | Glycoprotein compositions. |
DK1545613T3 (en) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatin conjugates and their use in the treatment of cancer, an autoimmune disease or an infectious disease |
WO2004019993A1 (en) | 2002-08-30 | 2004-03-11 | Ramot At Tel Aviv University Ltd. | Self-immolative dendrimers releasing many active moieties upon a single activating event |
JP2006507322A (en) | 2002-11-14 | 2006-03-02 | シンタルガ・ビーブイ | Prodrugs constructed as multiple self-detaching release spacers |
WO2004073656A2 (en) | 2003-02-20 | 2004-09-02 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
US7375078B2 (en) | 2004-02-23 | 2008-05-20 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
CN104611245A (en) | 2004-04-15 | 2015-05-13 | 格利科菲公司 | Production of galactosylated glycoproteins in lower eukaryotes |
AU2006269940C1 (en) | 2005-07-18 | 2013-11-07 | Seagen Inc. | Beta-glucuronide-linker drug conjugates |
EP1994000B1 (en) | 2006-02-02 | 2017-08-23 | Syntarga B.V. | Water-soluble cc-1065 analogs and their conjugates |
MX2010005857A (en) | 2007-11-28 | 2010-11-22 | Mersana Therapeutics Inc | Biocompatible biodegradable fumagillin analog conjugates. |
US20100152725A1 (en) | 2008-12-12 | 2010-06-17 | Angiodynamics, Inc. | Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation |
CN102448469A (en) | 2009-05-28 | 2012-05-09 | 摩萨纳医疗有限公司 | Polyal (ketone) drug conjugates comprising variable rate-releasing linkers |
JP2013528665A (en) | 2010-03-26 | 2013-07-11 | メルサナ セラピューティックス, インコーポレイテッド | Modified polymers for delivery of polynucleotides, methods for their production, and methods of their use |
US8889675B2 (en) * | 2011-10-14 | 2014-11-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
TWI571466B (en) * | 2011-10-14 | 2017-02-21 | 艾伯維有限公司 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
IN2014CN04961A (en) | 2011-12-05 | 2015-09-18 | Igenica Biotherapeutics Inc | |
CN104024236A (en) | 2011-12-23 | 2014-09-03 | 摩萨那医疗公司 | Pharmaceutical formulations for fumagillin derivative-phf conjugates |
SG10201608904YA (en) | 2012-05-15 | 2016-12-29 | Seattle Genetics Inc | Self-Stabilizing Linker Conjugates |
US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
US20140017265A1 (en) | 2012-07-05 | 2014-01-16 | Mersana Therapeutics, Inc. | Terminally Modified Polymers and Conjugates Thereof |
CA2892863C (en) | 2012-12-10 | 2022-03-15 | Mersana Therapeutics, Inc. | Polymeric scaffold based on phf for targeted drug delivery |
US10226535B2 (en) | 2012-12-10 | 2019-03-12 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
EP2931316B1 (en) | 2012-12-12 | 2019-02-20 | Mersana Therapeutics, Inc. | Hydroxyl-polymer-drug-protein conjugates |
CN110841074B (en) | 2014-03-21 | 2023-07-18 | 艾伯维公司 | anti-EGFR antibodies and antibody drug conjugates |
MX2017007629A (en) * | 2014-12-09 | 2018-05-17 | Abbvie Inc | Bcl xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same. |
WO2016094517A1 (en) * | 2014-12-09 | 2016-06-16 | Abbvie Inc. | Bcl-xl inhibitory compounds and antibody drug conjugates including the same |
MX2017007641A (en) * | 2014-12-09 | 2017-10-02 | Abbvie Inc | Antibody drug conjugates with cell permeable bcl-xl inhibitors. |
-
2017
- 2017-06-07 MX MX2018015286A patent/MX2018015286A/en unknown
- 2017-06-07 EP EP17731394.7A patent/EP3468996B1/en not_active Withdrawn - After Issue
- 2017-06-07 BR BR112018075636-9A patent/BR112018075636A2/en unknown
- 2017-06-07 PE PE2018003191A patent/PE20190512A1/en unknown
- 2017-06-07 KR KR1020197000330A patent/KR20190015526A/en active IP Right Grant
- 2017-06-07 KR KR1020237007108A patent/KR20230035690A/en active Application Filing
- 2017-06-07 EP EP22166591.2A patent/EP4104865A1/en active Pending
- 2017-06-07 AU AU2017277517A patent/AU2017277517A1/en active Pending
- 2017-06-07 US US16/308,463 patent/US20190343961A1/en not_active Abandoned
- 2017-06-07 CN CN202211269794.2A patent/CN116059202A/en active Pending
- 2017-06-07 JP JP2018564215A patent/JP2019521106A/en active Pending
- 2017-06-07 SG SG11201810970WA patent/SG11201810970WA/en unknown
- 2017-06-07 CA CA3027178A patent/CA3027178A1/en active Pending
- 2017-06-07 CN CN202211269635.2A patent/CN116059201A/en active Pending
- 2017-06-07 TW TW106118952A patent/TW201806626A/en unknown
- 2017-06-07 SG SG10201914060WA patent/SG10201914060WA/en unknown
- 2017-06-07 CR CR20180614A patent/CR20180614A/en unknown
- 2017-06-07 CN CN202211269863.XA patent/CN116059394A/en active Pending
- 2017-06-07 RU RU2018147224A patent/RU2018147224A/en not_active Application Discontinuation
- 2017-06-07 TW TW111128039A patent/TW202320860A/en unknown
- 2017-06-07 IL IL308054A patent/IL308054A/en unknown
- 2017-06-07 CN CN201780048216.7A patent/CN109563168A/en active Pending
- 2017-06-07 WO PCT/US2017/036368 patent/WO2017214282A1/en unknown
-
2018
- 2018-12-07 DO DO2018000272A patent/DOP2018000272A/en unknown
- 2018-12-07 IL IL263571A patent/IL263571A/en unknown
- 2018-12-07 MX MX2022007807A patent/MX2022007807A/en unknown
- 2018-12-07 CL CL2018003527A patent/CL2018003527A1/en unknown
- 2018-12-10 PH PH12018502602A patent/PH12018502602A1/en unknown
- 2018-12-13 CO CONC2018/0013497A patent/CO2018013497A2/en unknown
-
2019
- 2019-01-03 EC ECSENADI2019157A patent/ECSP19000157A/en unknown
- 2019-08-09 CL CL2019002270A patent/CL2019002270A1/en unknown
-
2021
- 2021-09-10 US US17/447,362 patent/US20230077680A1/en active Pending
- 2021-12-13 JP JP2021201460A patent/JP2022058351A/en active Pending
-
2022
- 2022-03-02 IL IL291073A patent/IL291073A/en unknown
- 2022-09-09 DO DO2022000182A patent/DOP2022000182A/en unknown
-
2023
- 2023-08-10 JP JP2023130710A patent/JP2023166395A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL291073A (en) | Anti-egfr antibody drug conjugates | |
IL265309A (en) | Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates | |
IL247936A0 (en) | Anti-egfr antibodies and antibody drug conjugates | |
IL267003A (en) | Multi-drug antibody drug conjugates | |
HK1232123A1 (en) | Hydrophilic antibody drug conjugates | |
IL252015A0 (en) | Antibody drug conjugates | |
IL251938A0 (en) | Anti-cs1 antibodies and antibody drug conjugates | |
IL250189A0 (en) | Anti-cdh6 antibody drug conjugates | |
HUE050398T2 (en) | Anti-cmet antibody drug conjugates and methods for their use | |
IL259651A (en) | Site specific her2 antibody drug conjugates | |
IL267834B1 (en) | Anti-ccr7 antibody drug conjugates | |
EP3250238A4 (en) | Antibody drug conjugates | |
IL250319A0 (en) | Stability-modulating linkers for use with antibody drug conjugates | |
SG10202002153PA (en) | Glycoengineered antibody drug conjugates | |
IL274650A (en) | Anti-cd40 antibody drug conjugates | |
EP3253212A4 (en) | Antibody drug conjugates | |
PL3544634T3 (en) | Met antibody drug conjugates | |
LU92659B1 (en) | Glycooptimized antibody drug conjugates | |
EP3411382A4 (en) | Anti-egfr antibody drug conjugate |